Corporate Governance

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda markets two FDA-approved therapies, including INBRIJA® (levodopa inhalation powder) 42 mg capsules.

Corporate Governance Guidelines

Code of Ethics

Download

Committee Charters

Below is a summary of our committee structure and membership information. Please note, John Kelley serves as Acorda's non-executive Chair of the Board. To read more about any of the committees, click on the committee names in the chart below.

  • ChairpersonChairperson
  • MemberMember
  • Financial ExpertFinancial Expert
Committee Composition Table
  Audit Committee Compensation Committee Nomination
& Governance Committee
Business Development
Peder Jensen Member Member
John Kelley Financial Expert Member Chairperson Member
Sandra Panem, Ph.D. Member Chairperson
Lorin J. Randall Financial Expert Chairperson Member

Chairperson Chairperson
Member Member
Financial Expert Financial Expert
Lorin J. RandallFinancial Expert Chairperson
Peder Jensen Member
John Kelley Member
John Kelley Chairperson
Sandra Panem, Ph.D. Member
Lorin J. RandallFinancial Expert Member
Sandra Panem, Ph.D. Chairperson
Peder Jensen Member
John Kelley Member

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At COMPANY NAME, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to COMPANY NAME to send you the requested Investor Email Alert updates.

* Required